$RARE earnings report

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027. AlphAI read Ultragenyx Pharmaceutical's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readRARE · Third Quarter 2026 · ended September 30, 2026

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

→Mixed quarter

Third-quarter revenue and the net loss improved from the prior-year period, supported by product revenue growth and lower research and development expense, while the company remained loss-making, held a stockholders' deficit, and initiated substantial headcount and program reductions.

Revenue
$173M
CRYSVITA - Total Revenue
$109M
EPS · GAAP
$(1.16)
Full year 2026 and 2027 outlook
Full year 2026 total revenue of $730 million to $760 million, excluding revenue from new product launches; full year 2026 CRYSVITA revenue of $500 million to $520 million; full year 2026 DOJOLVI revenue of $100 million to $110 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues - Three Months Ended September 30, 2026GAAP$173M––
Product sales - Three Months Ended September 30, 2026GAAP$105M––
Royalty revenue - Three Months Ended September 30, 2026GAAP$68M––
Cost of sales - Three Months Ended September 30, 2026GAAP$32M––
Research and development - Three Months Ended September 30, 2026GAAP$154M––
Selling, general and administrative - Three Months Ended September 30, 2026GAAP$97M––
Total operating expenses - Three Months Ended September 30, 2026GAAP$283M––
Loss from operations - Three Months Ended September 30, 2026GAAP−$110M––
Non-cash interest expense on liabilities for sales of future royalties - Three Months Ended September 30, 2026GAAP−$20M––
Other income, net - Three Months Ended September 30, 2026GAAP$3M––
Loss before income taxes - Three Months Ended September 30, 2026GAAP−$127M––
Benefit from (provision for) income taxes - Three Months Ended September 30, 2026GAAP$9M––
Net loss - Three Months Ended September 30, 2026GAAP−$118M––
Net loss per share, basic and diluted - Three Months Ended September 30, 2026GAAP$(1.16) per share––
Shares used in computing net loss per share, basic and diluted - Three Months Ended September 30, 2026GAAP102.1M––
Non-cash stock-based compensation - Three Months Ended September 30, 2026GAAP$34M––
Restructuring expense - Three Months Ended September 30, 2026GAAP—––
Total revenues - Nine Months Ended September 30, 2026GAAP$523M––
Product sales - Nine Months Ended September 30, 2026GAAP$306M––
Royalty revenue - Nine Months Ended September 30, 2026GAAP$217M––
Cost of sales - Nine Months Ended September 30, 2026GAAP$96M––
Research and development - Nine Months Ended September 30, 2026GAAP$508M––
Selling, general and administrative - Nine Months Ended September 30, 2026GAAP$273M––
Total operating expenses - Nine Months Ended September 30, 2026GAAP$877M––
Loss from operations - Nine Months Ended September 30, 2026GAAP−$354M––
Non-cash interest expense on liabilities for sales of future royalties - Nine Months Ended September 30, 2026GAAP−$63M––
Other income, net - Nine Months Ended September 30, 2026GAAP$15M––
Loss before income taxes - Nine Months Ended September 30, 2026GAAP−$402M––
Benefit from (provision for) income taxes - Nine Months Ended September 30, 2026GAAP$7M––
Net loss - Nine Months Ended September 30, 2026GAAP−$395M––
Net loss per share, basic and diluted - Nine Months Ended September 30, 2026GAAP$(3.89) per share––
Shares used in computing net loss per share, basic and diluted - Nine Months Ended September 30, 2026GAAP101.6M––
Non-cash stock-based compensation - Nine Months Ended September 30, 2026GAAP$98M––
Restructuring expense - Nine Months Ended September 30, 2026GAAP$30M––

Segments

SegmentRevenueq/qy/y
CRYSVITA - Total RevenueConsistent with expected ordering patterns.$109M––
CRYSVITA - Product sales - Latin America and TürkiyeNot provided.$41M––
CRYSVITA - Royalty revenue - U.S. and CanadaNot provided.$61M––
CRYSVITA - Royalty revenue - EuropeNot provided.$7M––
DOJOLVINot provided.$30M––
EVKEEZAIncreased demand from new country launches and early access.$24M––
MEPSEVIINot provided.$10M––

Full year 2026 and 2027 outlook

  • RevenueFull year 2026 total revenue of $730 million to $760 million, excluding revenue from new product launches; full year 2026 CRYSVITA revenue of $500 million to $520 million; full year 2026 DOJOLVI revenue of $100 million to $110 million
  • Operating expenses2027 R&D expenses of less than $350 million; 2027 SG&A expenses of less than $375 million
  • NoteFull-year GAAP profitability in 2027 and going forward.
  • NoteFourth quarter 2026 financial results are expected to include approximately $25 million of severance and other non-recurring restructuring charges.
  • NoteThe reduction in force is expected to be substantially completed by the end of 2026.
  • NoteNet proceeds from both PRV sales are expected to be approximately $350 million.
  • NoteDTX301 Phase 3 Enh3ance data are expected in the first half of 2027.

What drove it

  • Third-quarter total revenue was $173 million, including $109 million of CRYSVITA revenue, $30 million of DOJOLVI revenue, $24 million of EVKEEZA revenue and $10 million of MEPSEVII revenue.
  • EVKEEZA revenue was driven by increased demand from new country launches and early access.
  • FDA granted accelerated approval for GENGLYCOS in August 2026 and standard full approval for FAYUVI in September 2026.
  • The company is focused on commercial execution, successful GENGLYCOS and FAYUVI launches, and continued growth in current product revenues.
  • The company initiated substantial headcount and expense reductions after completing late-stage development programs.

Concerns

  • The company reported a net loss of $(118) million for the third quarter and a net loss of $(395) million for the nine months ended September 30, 2026.
  • Total stockholders' deficit was $(376) million as of September 30, 2026.
  • The company is reducing headcount by approximately 20%, with a revised workforce of approximately 1,000 employees.
  • The company is completing the wind-down of all ongoing GTX-102 studies and terminating UX701 after the program did not meet criteria to advance to the pivotal Phase 3 stage.
  • The FAYUVI PRV sale is expected to close later in November 2026, and the company states that PRV sales may not close on the expected timeline or at all.
  • GENGLYCOS received accelerated approval and is subject to confirmatory study requirements; the FDA may withdraw accelerated approval if confirmatory studies do not verify clinical benefit.

What to watch

  • Closing of the FAYUVI PRV sale and receipt of expected net proceeds from both PRV sales.
  • Execution of the approximately 20% headcount reduction, targeted expense reductions and expected fourth-quarter restructuring charges.
  • Commercial launches and demand for GENGLYCOS and FAYUVI.
  • Delivery of the second primary endpoint data from the DTX301 Phase 3 Enh3ance study in the first half of 2027.
  • Regulatory engagement to determine whether there is a potential path forward for UX143.
  • Progression of UX016, for which dosing is to be initiated soon and the Phase 1/2 study is funded through clinical proof-of-concept by an external venture philanthropy agreement.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026, compared with $737 million as of December 31, 2025.
  • Working capital was $155 million as of September 30, 2026, compared with $567 million as of December 31, 2025.
  • Total assets were $1,187 million as of September 30, 2026, compared with $1,532 million as of December 31, 2025.
  • Total stockholders' deficit was $(376) million as of September 30, 2026, compared with $(80) million as of December 31, 2025.
  • Net cash used in operations was $43 million for the three months ended September 30, 2026.
  • The GENGLYCOS PRV was sold for $210 million.
  • The FAYUVI PRV is under a definitive agreement for $203 million.
  • The two PRVs are under agreement for a combined sales price of $413 million. Net proceeds from both sales are expected to be approximately $350 million.

Analysis

Ultragenyx reported third-quarter total revenue of $173 million, compared with $160 million in the prior-year quarter. Product sales were $105 million and royalty revenue was $68 million. CRYSVITA generated $109 million, described as consistent with expected ordering patterns, while DOJOLVI contributed $30 million. EVKEEZA revenue was $24 million and was driven by increased demand from new country launches and early access. Nine-month total revenue was $523 million, compared with $466 million in the prior-year period.

The loss narrowed during the quarter as research and development expense declined to $154 million from $216 million, more than offsetting higher cost of sales and selling, general and administrative expense. Total operating expenses were $283 million, compared with $331 million, and loss from operations was $(110) million, compared with $(171) million. Net loss was $(118) million, or $(1.16) per share basic and diluted, versus $(180) million, or $(1.81) per share. The company also recorded $34 million of non-cash stock-based compensation in the quarter.

Management is undertaking a material reshaping of the cost base. The company expects to reduce headcount by approximately 20% to a revised workforce of approximately 1,000 employees, reduce 2027 R&D expenses to less than $350 million, and reduce 2027 SG&A expenses to less than $375 million. It is winding down GTX-102 studies, terminating UX701, reducing its real estate footprint, and expects approximately $25 million of severance and other non-recurring restructuring charges in fourth-quarter 2026 results. The company continues to anticipate full-year GAAP profitability in 2027 and going forward.

Liquidity and near-term funding are also central to the reported period. Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026, while net cash used in operations was $43 million for the quarter. The GENGLYCOS PRV sale closed for $210 million, and the FAYUVI PRV is under agreement for $203 million, with combined expected net proceeds of approximately $350 million. The company reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million, excluding new product launches, as well as CRYSVITA and DOJOLVI revenue guidance.

The operating focus is shifting toward execution of GENGLYCOS and FAYUVI launches, growth of existing products, and a smaller targeted pipeline. Upcoming development priorities include first-half 2027 data from the DTX301 Phase 3 Enh3ance study and regulatory discussions on UX143. The reported period also includes meaningful pipeline contraction through the UX701 termination and GTX-102 wind-down, while GENGLYCOS carries confirmatory study requirements associated with its accelerated approval.

Management, verbatim

We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products.

Emil D. Kakkis, M.D., Ph.D., chief executive officer and president

With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.

Emil D. Kakkis, M.D., Ph.D., chief executive officer and president

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Non-GAAP revenue, earnings, operating income, net income, EPS, or cash flow measures were not reported.
  • Prior-quarter comparisons were not reported for the financial statement metrics.
  • Percentage year-over-year and quarter-over-quarter changes were not reported for the financial statement and product revenue metrics.
  • Free cash flow, capital expenditures, and investing cash flow were not reported.
  • Debt balances and maturities were not reported.
  • Share repurchases and dividends were not reported.
  • A previous outlook section was not provided, so prior-guidance comparisons cannot be made.
  • A tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readRARE · Second Quarter 2026 · ended June 30, 2026

Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million

✓Solid quarter

Second-quarter revenue reached the highest quarterly level in the company’s history, total revenue increased versus the prior-year quarter, net loss narrowed, and the company reaffirmed 2026 revenue and expense guidance. The period remains loss-making, with $97 million of net cash used in operations and substantial upcoming regulatory and clinical catalysts.

Revenue
$214M
Crysvita®
$156M
EPS · GAAP
$0.90
full year 2026 outlook
$730 million to $760 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$214M––
Cost of salesGAAP$34M––
Research and developmentGAAP$167M––
Selling, general and administrativeGAAP$88M––
Total operating expensesGAAP$289M––
Non-cash stock-based compensationother$34M––
Net lossGAAP$92M––
Net loss per share, basic and dilutedGAAP$0.90 per share basic and diluted––
Six Months Ended June 30 Total revenuesGAAP$350M––
Six Months Ended June 30 Cost of salesGAAP$64M––
Six Months Ended June 30 Research and developmentGAAP$354M––
Six Months Ended June 30 Selling, general and administrativeGAAP$176M––
Six Months Ended June 30 Total operating expensesGAAP$594M––
Six Months Ended June 30 Net lossGAAP$277M––
Six Months Ended June 30 Net loss per share, basic and dilutedGAAP$2.73 per share basic and diluted––

Segments

SegmentRevenueq/qy/y
Crysvita®Consistent with expected seasonality in the U.S. and Canada and ordering patterns in Latin America.$156M––
Dojolvi®Dojolvi was listed on the National Health Insurance drug price list and launched in Japan in May 2026.$27M––
Evkeeza®Driven by increased demand from new country launches and early access.$21M––
Mepsevii®$10M––

full year 2026 outlook

  • Revenue$730 million to $760 million
  • Operating expensescombined R&D and SG&A expenses in 2026 are expected to be flat to down low-single digits compared to 2025
  • NoteCrysvita revenue guidance of $500 million to $520 million
  • NoteDojolvi revenue guidance of $100 million to $110 million
  • NoteTotal revenue guidance excludes revenue from potential new product launches.
  • NoteCombined R&D and SG&A expenses in 2027 are expected to decrease by at least 15% compared to 2025.
  • NoteRemain on path to profitability in 2027.

What drove it

  • Total revenue in the second quarter of 2026 was $214 million.
  • Crysvita revenue was consistent with expected seasonality in the U.S. and Canada and ordering patterns in Latin America.
  • Evkeeza revenue was driven by increased demand from new country launches and early access.
  • Dojolvi launched in Japan in May 2026 following National Health Insurance drug price-list inclusion.
  • The company has PDUFA action dates for DTX401 on August 23, 2026 and UX111 on September 19, 2026.
  • Data from the GTX-102 Phase 3 Aspire study are expected in the September or October timeframe.

Concerns

  • The company reported a net loss of $92 million and net cash used in operations of $97 million for the three months ended June 30, 2026.
  • Total operating expenses were $289 million, including research and development expense of $167 million.
  • Crysvita revenue is subject to expected seasonality in the U.S. and Canada and ordering patterns in Latin America.
  • The company identifies dependence on Kyowa Kirin for commercialization and commercial supply of Crysvita in certain major markets, including the U.S. and Canada.
  • Potential approvals, launches, and clinical readouts remain subject to regulatory, clinical, manufacturing, reimbursement, and market-acceptance risks.

What to watch

  • DTX401 PDUFA action date of August 23, 2026.
  • UX111 PDUFA action date of September 19, 2026.
  • GTX-102 Phase 3 Aspire study data expected in the September or October timeframe.
  • Completion of enrollment in the GTX-102 Phase 2/3 Aurora study expected in the second half of 2026.
  • UX701 pivotal Cyprus2+ dose-finding-stage data expected in the fourth quarter of 2026.
  • UX016 externally funded Phase 1/2 study expected to begin in the second half of 2026.
  • DTX301 Phase 3 Enh3ance second-primary-endpoint data expected in the first half of 2027.
  • Delivery against full-year 2026 total revenue guidance of $730 million to $760 million and combined R&D and SG&A expense guidance.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $436 million as of June 30, 2026.
  • For the three months ended June 30, 2026, net cash used in operations was $97 million.

Analysis

Ultragenyx reported second-quarter total revenue of $214 million, compared with $167 million in the prior-year quarter. The company described this as its highest quarterly revenue in its history and reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million, excluding potential new-product-launch revenue. Crysvita contributed $156 million, while Dojolvi, Evkeeza, and Mepsevii contributed $27 million, $21 million, and $10 million, respectively.

Crysvita remains the largest reported product-revenue contributor. Management attributed its quarterly performance to expected seasonality in the U.S. and Canada and ordering patterns in Latin America. Dojolvi had been launched in Japan during May 2026 after National Health Insurance drug price-list inclusion. Evkeeza revenue was driven by increased demand from new country launches and early access. The company reaffirmed full-year Crysvita revenue guidance of $500 million to $520 million and Dojolvi guidance of $100 million to $110 million.

The company remained loss-making despite higher revenue. Total operating expenses were $289 million, compared with $275 million in the prior-year quarter, including $167 million of research and development expense and $88 million of selling, general and administrative expense. Net loss improved to $92 million from $115 million, while net loss per share improved to $0.90 from $1.17. The company reaffirmed that combined R&D and SG&A expenses in 2026 are expected to be flat to down low-single digits compared to 2025, and that such expenses in 2027 are expected to decrease by at least 15% compared to 2025.

Liquidity and cash consumption remain important. Cash, cash equivalents, and marketable securities were $436 million as of June 30, 2026, and net cash used in operations was $97 million for the quarter. No capital-return activity or debt balance was reported in the supplied release.

The second half of 2026 includes material regulatory and clinical events. DTX401 has an August 23, 2026 PDUFA action date, and UX111 has a September 19, 2026 PDUFA action date. GTX-102 Phase 3 Aspire data are expected in the September or October timeframe, UX701 data are expected in the fourth quarter of 2026, and DTX301 second-primary-endpoint data are expected in the first half of 2027. These events, together with the company’s stated path to profitability in 2027, are central to the outlook.

Management, verbatim

In the second quarter we generated the highest quarterly revenue in the history of the company, supporting our full-year revenue guidance, and keeping us on track toward profitability in 2027,

Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx

As we look to the second half of the year, we are entering a transformative period with multiple important catalysts. We are ready to launch two gene therapy products and are preparing for a pivotal Phase 3 GTX-102 data readout in Angelman syndrome. This puts us in position to broaden our patient impact with sustained growth in the years to come.

Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Operating income or loss
  • Non-GAAP revenue, earnings, EPS, or expense metrics
  • Prior-quarter comparisons for reported financial metrics
  • Reported year-over-year or quarter-over-quarter percentage changes for financial metrics and product revenues
  • Product revenue comparisons for Crysvita, Dojolvi, Evkeeza, and Mepsevii
  • Free cash flow
  • Debt balance
  • Capital returns, including share repurchases and dividends
  • Tax rate
  • Gross-margin guidance
  • Tax-rate guidance
  • Prior outlook section for comparison with reported results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about RARE earnings dates

When is Ultragenyx Pharmaceutical's next earnings date?
AlphAI has no date for RARE yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.